Form 4: Mersana Therapeutics Director Andrew Hack Granted 61,500 Stock Options

Mersana Therapeutics, Inc. director Andrew A. F. Hack was granted 61,500 stock options with an exercise price of $0.36, aligning his interests with the company's performance.

Summary

• Andrew A. F. Hack, a Director and 10% Owner of Mersana Therapeutics, Inc. (MRSN), was granted 61,500 stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $0.36.
• The options are exercisable immediately upon grant and have an expiration date of June 11, 2035.
• The award will vest in full on the earlier of the first anniversary of the grant date (June 12, 2026) or the date of the 2026 Annual Meeting of Stockholders of Mersana Therapeutics, Inc.
• Vesting is contingent upon Mr. Hack's continuous service with the Issuer on the vesting date.
• Following this transaction, Mr. Hack directly beneficially owns 61,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant of stock options to a director aligns their interests with shareholders, indicating commitment and incentivizing long-term value creation. This is a standard and generally well-received practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the value of the options increases with the company's stock price.
• The director's continued service, a condition for vesting, indicates ongoing commitment to the company.

Future Outlook

The stock options are subject to a vesting schedule, which will occur on the earlier of the first anniversary of the grant date (June 12, 2026) or the date of the 2026 Annual Meeting of Stockholders, provided the reporting person maintains continuous service.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, including for companies like Mersana Therapeutics, Inc., to incentivize long-term performance and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Equity compensation, particularly through stock options, is a common component of director remuneration across the U.S. public company landscape, including biotech firms.
• The specific exercise price and quantity are company-specific and depend on factors like the company's stock price at grant, the director's role, and the overall compensation philosophy, making direct comparisons without more context challenging. However, the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, such compensation practices for leadership can reflect the company's overall approach to incentivizing performance.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the date of the 2026 Annual Meeting of Stockholders, subject to continuous service.

Key Dates

Keywords

Mersana Therapeutics, MRSN, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Andrew Hack